Cell therapy for bone nonunion: A retrospective study

Minerva Medica

Volumn 106, Issue 6, 2015, Pages 315-321

  Qu, Z ^a,b   Fang, G ^a,b   Cui, Z ^a,b   Liu, Y ^a  

^a Siping Hospital of China Medical University   (China)

^b Tuhua Bioengineering Company Ltd   (China)

Author keywords

And Tissue based therapy; Cell; Stem cells; Umbilical cord

Indexed keywords

CD8 ANTIGEN;

ADHERENT CELL; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW MONONUCLEAR CELL TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD LEVEL; BONE MARROW DERIVED MONONUCLEAR CELL; BONE MASS; CALLUS; CELL THERAPY; CLINICAL ARTICLE; FEMALE; FOLLOW UP; FRACTURE HEALING; HUMAN; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; PSEUDARTHROSIS; RADIODIAGNOSIS; RETROSPECTIVE STUDY; SURGICAL APPROACH; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; UMBILICAL CORD; BIOLOGICAL THERAPY; BONE MARROW CELL; COMPARATIVE STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; FRACTURES, UNUNITED; MIDDLE AGED; MONOCYTE; PATHOLOGY; PROCEDURES; RISK FACTOR; TIME FACTOR; TRANSPLANTATION;

ADULT; BONE MARROW CELLS; CELL- AND TISSUE-BASED THERAPY; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; FOLLOW-UP STUDIES; FRACTURE HEALING; FRACTURES, UNUNITED; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MONOCYTES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84961994323     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Rodriguez IA, Growney Kalaf EA, Bowlin GL, Sell SA. Platelet-rich plasma in bone regeneration: engineering the delivery for improved clinical efficacy. Biomed Res Int 2014;2014:392-8.
2. Younger EM, Chapman MW. Morbidity at bone graft donor sites. J Orthopaed Traum 1989;3:192-5.
3. Corsi KA, Schwarz EM, Mooney DJ, Huard J. Regenerative medicine in orthopaedic surgery. J Orthop Res 2007;25:1261-8.
4. Miller MA, Ivkovic A, Porter R, Harris MB, Estok DM 2nd, Smith RM, Evans CH, Vrahas MS. Autologous bone grafting on steroids: preliminary clinical results. A novel treatment for nonunions and segmental bone defects. Int Orthop 2011;35:599-605.
5. Pecina M, Vukicevic S. Biological aspects of bone, cartilage and tendon regeneration. Int Orthop 2007;31:719-20.
6. Parckkadan B and Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 2010;12:87-117.
7. Hauzeur JP and Gangji V. Phases 1-3 clinical trials using adult stem cells in osteonecrosis and nonunion fractures. Stem Cells Int. 2010;2010:410170.
8. Qu Z, Guo L, Fang G, Guo S, Liu Y. Biological characteristics and effect of human umbilical cord mesenchymal stem cells (hUC-MSCs) grafting with blood plasma on bone regeneration in rats. Cell Biochem Biophys 2012;171-81.
9. Qu Z, Guo S, Fang G. AKT pathway affect bone regeneration in nonunion treated with umbilical cord-derived mesenchymal stem Cell. Biochem Biophys 2014 [Epub ahead of print].
10. Tian NF, Hu XQ, Wu LJ, Wu XL, Wu YS, Zhang XL, et al. Pooled analysis of non-union, re-operation, infection, and approach-related complications after anterior odontoid screw fixation. PLoS One 2014;9:e103065.
11. Qu ZG, Liu Y. Percutaneous radiological autologous bone-marrow mesenchymal stem cells grafting integrating with blood plasma by injection in the part of thigh fracture: seven-month follow-up effect evaluation in one case. J Clin Reh Tis Eng Res 2009;13:7393-6.
12. Lindenmair A, Hatlapatka T, Kollwig G, Hennerbichler S, Gabriel C, Wolbank S, et al. Mesenchymal Stem or Stromal Cells from Amnion and Umbilical Cord Tissue and Their Potential for Clinical Applications. Cells 2012;11061-88.
13. McGuirk JP, Smith JR, Divine CL, Zuniga M, Weiss ML. Wharton's Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease. Pharmaceuticals 2015;8:196-220.
14. Frausina S, Viventi S, Verga Falzacappa L, Quattromani MJ, Leanza G, Tommasini A, et al. Wharton's jelly derived mesenchymal stromal cells: Biological properties, induction of neuronal phenotype and current applications in neurodegeneration research. Acta Histochemica 2015;117:329-38.
15. Tokiko Nagamura-Inoue, Haiping He. Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility. World J Stem Cells 2014;6:195-202.
16. Chen MY, Lie PC, Li ZL, Wei X. Endothelial differentiation of Wharton's jelly-derived mesenchymal stem cells in comparison with bone marrowderived mesenchymal stem cells. Exp Hematol 2009;37:629-40.
17. Weiss ML and Troyer DL. Stem Cells in the Umbilical Cord. Stem Cell Rev 2006;2:155-62.
18. Venugopal P, Balasubramanian S, Majumdar AS, Ta M. Isolation, characterization, and gene expression analysis of Wharton's jelly-derived mesenchymal stem cells under xeno-free culture conditions. Stem Cells Cloning 2011;4:39-50.
19. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immuno. 2006;36:2566-73.